Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth: A study with cathepsin-L-deficient micey

American Journal of Pathology

Volumn 161, Issue 6, 2002, Pages 2047-2052

  Nishimura, Fusanori ^a   Naruishi, Hisa ^a   Naruishi, Koji ^a   Yamada, Teruo ^a   Sasaki, Junzo ^a   Peters, Christoph ^c   Uchiyama, Yasuo ^b   Murayama, Yoji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM ION; CATHEPSIN B; CATHEPSIN L; MESSENGER RNA; NIFEDIPINE; THAPSIGARGIN;

ACANTHOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; FIBROBLAST; GINGIVA OVERGROWTH; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; MUCOLIPIDOSIS TYPE 2; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036899127     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64483-5     Document Type: Article

References (26)

1. Blood Pressure Lowering Treatment Trialists' Collaboration: Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews randomised trials. Lancet 2000, 356:1955-1964
2. Ramon Y, Behar S, Kishon Y, Engelberg IS: Gingival hyperplasia caused by nifedipine: A preliminary report. Int J Cardiol 1984, 5:195-206
3. Steele RM, Schuna AA, Schreiber RT: Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994, 120:663-664
4. Mattila KJ, Valle MS, Niemien MS, Valtonen VV, Hietaniemi KL: Dental infections and cororary atherosclerosis. Atherosclerosis 1993, 103: 205-211
5. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT: Periodontal disease and risk of cerebrovascular disease: The first national health and nutrition examination survey and its follow-up study. Arch Intern Med 2000, 160:2749-2755
6. Leehy DJ, Song RH, Alavi N, Singh AK: Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 1995, 44:929-935
7. Ling H, Ardjomand P, Samvakas S, Simm A, Busch GL, Lang F, Sebekava K, Heidland A: Mesangial cell hypertrophy induced by NH4Cl: Role of depressed activities of cathepsins due to elevated lysosomal pH Kidney Int 1998, 53:1706-1712
8. Huang S, Schaefer RM, Reisch S, Paczek L, Schaefer L, Teschner M, Sebekova K, Heidland A: Suppressed activities of cathepsins and metalloproteinases in the chronic model of puromycin aminonucleoside nephrosis. Kidney Blood Press Res 1999, 22:121-127
9. Stypmann J, Gläser K, Roth W, Tobin DJ, Petermann I, Mattias R, Mönnig G, Haverkamp W, Breithard G, Schmahl W, Peters C, Reinheckel T: Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 2002, 99: 6234-6239
10. Bohley P, Seglen PO: Proteases and proteolysis in the lysosome. Experientia 1992, 48:151-157
11. Hasilik A, Waheed A, von Figura K: Enzymatic phosphorylation of lysosomal enzymes in the presence of UDP-N-acetylglucosamine: Absence of the activity in I-cell fibroblasts. Biochem Biophys Res Commun 1981, 98:761-767
12. Reitman ML, Varki A, Kornfeld S: Fibroblasts from patients with I-cell disease and pseudo-Hurler polydystrophy are deficient in uridine 5′-diphosphate-N-acetylglucosamine: Glycoprotein N-acetylglucosaminylphosphotransferase activity. J Clin Invest 1981, 67:1574-1579
13. Kopitz J, Arnold A, Meissner T, Cantz M: Protein catabolism in fibroblasts cultured from patients with mucolipidosis II and other lysosomai disorders. Biochem J 1993, 295:577-580
14. Whelan DT, Chang PL, Cockshott PW: The clinical, radiological, and biochemical features in three cases. Clin Genet 1983, 24:90-96
15. Taylor NG, Shuff RY: I-cell disease: An unusual cause of gingival enlargement Br Dent J 1994, 176:106-108
16. Nishimura F, Terranova VP: Comparative study of the chemotactic responses of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. J Dent Res 1996, 75:986-992
17. Barrett AJ, Kirschke H: Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol 1981, 80:535-561
18. Quian F, Bajkowski AS, Steiner DF, Chan SJ, Frankfater A: Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res 1989, 49:4870-4875
19. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, Schmidt P, Schmahl W, Scherer J, Anton-Lamprecht I, von Figura K, Paus R, Peters C: Cathepsin L deficiency as molecular defect of furless: Hyperproliferation of keratinocytes and pertubation of hair follicle cycling EMBO J 2000, 14:2075-2086
20. Yamada H, Nishimura F, Naruishi K, Chou H-H, Takashiba S, Albright GM, Nares S, lacopino AM, Murayama Y: Phenytoin and cyclosporin-A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol 2000, 71:955-960
21. Asahara Y, Nishimura F, Yamada H, Naruishi K, Kataoka M, Kido J, Nagata T, Murayama Y: Mast cells are not involved in the development of cyclosporin-A-induced gingival hyperplasia: A study with mast cell deficient mice. J Periodontol 2000, 71:1117-1120
22. Bakhshi R, Goel A, Seth P, Chhikara P, Chauhan SS: Cloning and characterization of human cathepsin-L promoter. Gene 2001, 275: 93-101
23. Chauhan SS, Goldstein LJ, Gottesman MM: Expression of cathepsin L in human tumors. Cancer Res 1991, 51:1478-1481
24. Gottesman MM, Sobel ME: Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA. Cell 1980, 19:449-455
25. Troen BR, Chauhan SS, Ray D, Gottesman MM: Downstream sequences mediate induction of the mouse cathepsin L promoter by phorbol esters. Cell Growth Differ 1991, 2:23-31
26. Mason RW, Johnson DA, Barrett AJ, Chapman HA: Elastinolytic activity of human cathepsin L. Biochem J 1986, 233:925-927